SecBot SecBot
SECBOTREPLAY Home › Report › GSK

GSK · GSK announced positive Phase II data for its mRNA seasonal flu vaccine…

GSK plc · 6-K filed Sep 1, 2026 at 07:46 ET

At the news

BULLISHIMPACT 6/10

6-K filed Sep 1, 2026 at 07:46 ET

GSK announced positive Phase II data for its mRNA seasonal flu vaccine candidate (FLUm3HA.b-3NA), showing higher immune responses vs. standard and high-dose vaccines in younger and older adults. The candidate targets both HA and NA antigens, a novel approach for mRNA flu vaccines. GSK will initiate a Phase III efficacy trial in September 2026, and the FDA granted Fast Track designation in July 2026. This is a positive pipeline catalyst but remains early-stage with no near-term revenue impact.

  • Phase II data showed higher immune responses vs. standard and high-dose flu vaccines in younger and older adults.
  • GSK intends to start a Phase III efficacy trial in September 2026.
  • FDA granted Fast Track designation in July 2026.
  • Vaccine candidate targets both haemagglutinin (HA) and neuraminidase (NA) antigens.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access